Jade Mallette

Issues with respect to the implementation of Bill C-64, An Act respecting pharmacare Work with the Government of Canada to bolster and create pan-Canadian standardized health data and digital tools to better track and have an up-to-date picture of diabetes and it's evolving impacts. Increase funds for diabetes in the Federal Budget specifically to increase funds directed to the Canadian Diabetes Strategy to reflect growth in diabetes prevalence and cost. Increase Federal funding for Diabetes Research - work directed towards increasing funding to federal granting councils, in particular the Canadian Institutes of Health Research (CIHR) through the Federal Budget. Funding for Implementation of the Framework for Diabetes tabled by the Minister of Health on October 5, 2022.

Increase funds for diabetes in the Federal Budget specifically to increase funds directed to the Framework for Diabetes in Canada its components and a strategy to reflect growth in diabetes prevalence and cost. Bill C-64 - An Act Respecting Pharmacare Increase Federal funding for Diabetes Research - work directed towards increasing funding to federal granting councils, in particular CIHR through the Federal Budget. Aboriginal Diabetes Initiative - work towards making funding for this Initiative permanent. (Previous work directed towards continuation of funding beyond 2010).

Engagement with government and parliamentary representatives with respect to pharmacare legislation and policy development.

Seek increased funding for type 1 diabetes research Discussions and information sharing on improving regulatory pathways for cell and gene therapy Discussions and information sharing around: Procurement and tariffs impact Insulin production Stock piles To seek funding to expand the foundation's educational program to raise awarenes of type 1 diabetes and diabetes management in Canada. Ensuring Bill C-64, the National Pharmacare Act, meets the needs of Canadians living with type 1 diabetes by having adequate insulin and diabetes devices coverage, while respecting patient choice. Seek an increase funding for the Canadian Clinical Trial Network to find a cure for Type 1 Diabetes (T1D). Ongoing conversation with Health Minister's Office regarding JDRF-CIHR Partnership to Defeat Diabetes renewal funding. Meeting with Juvenile Diabetes Caucus Co-Chairs to discuss strategies and tactics to move JDRF Canada Pre-Budget Submission priorities forward including additional funding for research towards a cure for type 1 diabetes Canadian Institutes of Health Research (CIHR) and the Strategy for Patient-Orientated Research (SPOR) Discussions with CIHR and SPOR Network about collaboration towards the creation of a type 1 diabètes registry

Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable.

Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets including by ensuring that company employees based abroad can travel to Canada, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable.

Follow up to the 2023 Parliamentary Review of Medical Assistance in Dying (MAID) report and any legislation that arise thereto in respect of advance requests, mature minors, MAID for those whose sole underlying condition is a mental illness, the state of palliative care and the protection of Canadians living with disabilities. Conscience rights of clinicians and the need for effective referral for patients. Access of persons across Canada to lawful medical procedures that are provided for under the Canada Health Act. Regulations for the Monitoring of MAID and changes to requirements. Statistical reporting and data collection issues in relation to MAID, Tracks 1 and 2. MAID curriculum or educational initiatives. Legislation and regulation regarding alternative therapies that can be incorporated at end-of-life such as psilocybin. Proposed or implemented legislation or regulation related to medical assistance in dying and any work of the Special Joint Committee on MAID (AMAD). Policies or legislative measures concerning the provision of a guaranteed income or Universal Basic Income (UBI). Legislation and policies concerning the new Canada Disability Benefit Our pre-budget submission included proposals to fund the new CDB at a level that would lift many PWD out of poverty and ensure that the new benefit was not 'clawed back' by provincial governments or private insurance schemes to the detriment of the recipient. Legislation and policies concerning affordable housing initiatives at the federal level DWDC's pre-budget submission included requests for more affordable housing, help for the homeless, and funds to improve the quality of the housing stock for indigenous and aboriginal peoples both on reserve and off.

Canada's Drug Agency policies as it relates to reimbursement recommendation decision-making process and framework Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry. Federal policies that relate to possible models of pharmacare Federal Buy Canadian Procurement Policy as it relates to government drug procurement practices and the implications for the biopharmaceutical industry Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time-to-reimbursement and streamline federal/provincial listing processes Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations National Strategy for Drugs for Rare Diseases World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Intellectual Property Organization (WIPO) issues concerning the biopharmaceutical industry World Health Organization (WHO) issues concerning the biopharmaceutical industry Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Income Tax Act as it relates to biopharmaceutical products Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade agreements as they relate to the biopharmaceutical industry Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry

Income Tax Act as it relates to biopharmaceutical products National Strategy for Drugs for Rare Diseases Biomanufacturing and Life Sciences Strategy (BLSS) as it relates to the biopharmaceutical industry Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry Activities related to the Convention on Biological Diversity (CBD) including Digital Sequence Information (DSI) and an Access and Benefit Sharing (ABS) framework. World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility" World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits Proposed pharmacare legislation related to any future national pharmacare program Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB) Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19 Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry Free trade treaty agreement as they relate to The Canada-United States-Mexico Agreement (CUSMA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH) Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products Canada's Access to Medicines Regime with respect to ensuring that the p

Support the inclusion of human rights objectives by Canada in international fora Promoting the importance of the full range of sexual and reproductive health and rights in development assistance programming, in line with a human rights framework and best practices. This can include conversations about accountability frameworks, funding practices, and resourcing international development assistance Discussions with government (department TBD) to support a national strategy for comprehensive sexuality education, including gender-based violence education, and access to accurate sexual and reproductive health information in Canada and in the world. This might also include requests for funding to support this advocacy work. Discussions with government (department TBD) to improve access to contraceptives in Canada and internationally. This could include changes to policies and programmes as well as requests for funds for further advocacy or services in this area. Discussions with government (department TBD) to discuss policies and programmes that would increase access to abortions for people in Canada and globally. This could include requests for funding related to supporting abortion access, proposed regulations and proposed legislation.

Meeting with elected and non-elected officials regarding Pharmacare and Health related issues.

Discuss increasing incidents of violence against health care workers, prevention, and enforcement of existing laws. Support nursing students through targeted financial support such as paid preceptorships and federal grants. Support internationally educated nurses through establishing a collaborative, multi-stakeholder body hosted by Health Canada, to lead national strategy, planning and coordination for internationally educated nurses' registration, integration and support. Targeted funding of $1 billion as an initial investment to immediately begin to address the current health care workforce crisis experienced by provinces/territories across Canada, with funding focused on short and long-term goals. To achieve patient-centred quality care based on the WHO’s comprehensive health labour markets framework that would be acceptable to, and delivered by, the provinces/territories. Provide sustainable funding so nurses and other healthcare workers have access to mental health supports. In keeping with the recommendations of the Truth and Reconciliation Commission, establish specific targets and timelines for the admission and graduation of First Nations, Métis and Inuit health professionals in all postsecondary institutions and provide funding dedicated to indigenous nurse students. Implementing a Universal single-payer pharmacare program. Fund innovative retention and recruitment programs targeted at early-career, mid-career and late-career nurses. Establish a dedicated coordinating body to address critical health workforce data gaps based on global best practices on health workforce management. Address health workforce shortages through the implementation of a comprehensive, pan-Canadian health human resources strategy, in coordination with the provinces and territories, backed by sufficient funding and with real accountability for achieving desired health outcomes; and address critical data gaps through significantly enhancing existing health workforce data infrastructure to standardize data collection and analysis across workers, sectors and jurisdictions, with links to relevant patient information, healthcare utilization and outcome data, for more fit-for-purpose planning and tools available at the provincial, territorial, regional and training program level. In designing this, Canada should draw on global best practices in health workforce planning including in Australia and New Zealand.

HEALTH DATA INTEROPERBILITY: Provide CMA’s perspective as it relates to health data interoperability that would ensure providers have access to the right information at the right time when providing care, and improve patient outcomes and their health care experience. BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care. HARMFUL ONLINE CONTENT: Advocate to address the escalation of online harassment, intimidation, and threats of violence targeting physicians, other health workers, and anyone seeking health care treatment, including measures to strengthen the Criminal Code of Canada and the Canadian Human Rights Act. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed. HEALTH PROMOTION AND DISEASE PREVENTION: Increased investments in health and social-determinants-of-health related programs, including measures to address the opioid crisis, mental health and addictions, and the regulation of natural health products. ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of EHRs and EMRs in Canada, improved remuneration for the completion of federal health forms, the development of a Federal Disability Benefit, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, providing clarity and guidance on federal forms, and advocacy on discontinuing the requirement that employees present sick notes to their employers. The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs. Improve safeguards for Canadian health data. Improve labour mobility so physicians can work across the country. Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians. PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. MEDICAL MIS/DISINFORMATION: Provide CMA’s perspective on the impacts of medical misinformation and disinformation, including on public trust in science, medicine, and public health experts. INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key s

INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector including input on Bill C-27, and the means through which advancements can be foreseen and managed. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key stakeholders, including the public, physicians, patients/PWLE, policymakers, system leaders and others, in a dialogue on public-private healthcare. What we hear will inform CMA policy moving forward, and our recommendations for action at a national level. PHYSICIAN PARLIAMENTARIAN CAUCUS: advocate for the formation of a Physician Parliamentarian Caucus as a means of examining deficiencies in the health care system and proposing solutions. PHYSICAL, PSYCHOLOGICAL AND CULTURAL SAFETY: Advocate to address the challenges and opportunities for physical, psychological and cultural safety within Canada’s health system, including the implementation of a nation-wide anti-racism plan, the creation of a Canada Mental Health transfer, improving access to mental health services to physicians and their families, gender-affirming care, creating an emergency National Mental Health Support Services hotline for all health care providers, the creation of a National Physicians Day in Canada, ensuring safe and unimpeded access to health care facilities for health care workers and patients. PERSONAL INFORMATION PROTECTION AND ELECTRONIC DOCUMENT ACT (PIPEDA) PRIVACY PROTECTION OF HEALTH INFORMATION AND THE REGULATORY REVIEW: Improvement to privacy legislation to protect the privacy of health information. PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. NET ZERO: Advocate for sustainable health systems in Canada, including reaching net-zero emissions by 2050; advocate for the establishment of a national climate and health secretariat within the federal government to develop a pan-Canadian approach to addressing the impacts of climate change and health; and advocate for a targeted health infrastructure fund as part of the federal government’s long-term plan for public infrastructure. MEDICAL ASSISTANCE IN DYING: Advancing the medical profession’s perspectives on medical assistance in dying. INTEGRATED HEALTH HUMAN RESOURCES Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. INDIGENOUS HEALTH AND RECONCILIATION WITH INDIGENOUS PEOPLES: Implementation of the Calls to Action of the Truth and Reconciliation Commission, including addressing the ongoing structural inequities that marginalize Indigenous Peoples, advancing the inclusion of Indigenous Peoples in societal systems and sectors, including health systems, and committing to collaborative and respectful relationships with Indigenous patients and communities. The CMA is also advocating to increase trust between Ind

BUDGET: Provide CMA’s perspective on the Government of Canada’s budget, particularly as it relates to modernizing Canada’s health care system by enhancing efficiency, driving innovation, and promoting equitable access to care. HARMFUL ONLINE CONTENT: Advocate to address the escalation of online harassment, intimidation, and threats of violence targeting physicians, other health workers, and anyone seeking health care treatment, including measures to strengthen the Criminal Code of Canada and the Canadian Human Rights Act. TECHNOLOGY AND ARTIFICIAL INTELLIGENCE: provide CMA’s perspective on the impact of technology and artificial intelligence on the health care sector and the means through which advancements can be foreseen and managed. HEALTH DATA INTEROPERBILITY: Provide CMA’s perspective as it relates to health data interoperability that would ensure providers have access to the right information at the right time when providing care, and improve patient outcomes and their health care experience. The CMA is advocating that the trade of medical goods and medications be protected to avoid disruptions to patient care. Specifically, that the government: Continue to ensure pharmaceutical products and medical devices are not included in any countermeasures on tariffs. Improve safeguards for Canadian health data. Improve labour mobility so physicians can work across the country. Make it easier for qualified physicians to immigrate and work in Canada, including by fast-tracking immigration steps for US physicians. MEDICAL MIS/DISINFORMATION: Provide CMA’s perspective on the impacts of medical misinformation and disinformation, including on public trust in science, medicine, and public health experts. PAN CANADIAN LICENSURE: Advocate for the ability for physicians with full licences to practise independently without restrictions or for medical resident trainees registered in any Canadian jurisdiction to practise or train in any other Canadian jurisdiction without having to acquire more than one licence or pay additional licensing fees. This includes exploring enabling legislation in the provinces and territories. INTEGRATED HEALTH HUMAN RESOURCES: Advocate for an Integrated Health Human Resources Strategy, including creating retention incentives and addressing administrative burden for health care professionals, increasing the number of doctors and nurses and ensuring that every Canadian has access to a family doctor or primary health team, increasing access to virtual care, creating an action plan to get internationally trained health care professionals to work, improving workforce data collection across health systems and investing in a supply needs-based planning tool, and facilitating team-based health care. ADMINISTRATIVE BURDEN: Advocate for measures to alleviate the administrative burden on physicians and support their professional wellbeing, including investment to facilitate the development of EHRs and EMRs in Canada, improved remuneration for the completion of federal health forms, ensuring that physicians are not captured in the definition of "promoters" in the Disability Tax Credit Promoters Restrictions Regulations, and advocacy on discontinuing the requirement that employees present sick notes to their employers. INDIGENOUS HEALTH: Improvement to the health and health care services provided to Indigenous peoples in Canada, including adding inclusive lettering on health cards across Canada. Advocating for the creation of a national Chief Health Accountability Officer. PUBLIC-PRIVATE HEALTHCARE: The CMA is conducting a series of in-person sessions across the country to engage key stakeholders, including the public, physicians, patients/PWLE, policymakers, system leaders and others, in a dialogue on public-private healthcare. What we hear will inform CMA policy moving forward, and our recommendations for action at a national level. PHYSICIAN PARLIAMENTARIAN CAUCUS: advocate for the formation of a Physician Parliamentarian